Non-opioid pain therapies are entering an unprecedented era, marked by the landmark FDA approval of Vertex’s Journavx and a ...

Vertex's Chronic Pain Ambitions Hit Roadblock with LSR Data So much of Journavx's potential lies in chronic pain management. In December, Vertex revealed Phase 2 data evaluating Journavx in ...

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced management participation in three upcoming investor ...

Vertex’s medicine could therefore be an “amazing” addition, he said, as it may offer some relief not only after surgery, but in everyday pain management as well. Journavx might dull ...

Vertex said in a press release. Despite ICER’s characterization and the recent trial results, the drug would mark a milestone in acute pain management. “The anticipated approval of suzetrigine ...

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the U.S. Food and Drug Administration (FDA) has approved JOURNAVX™ (suzetrigine), an oral, non-opioid, highly selective ...

For Vertex these days, it’s all about the launches ... The measure increases access to non-opioid approaches to pain management in the hospital setting for those enrolled in Medicare.

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced management participation in ... transfusion-dependent beta thalassemia and acute pain, and it continues to advance clinical ...

The FDA's approval of the non-addictive painkiller Journavx last week marked a milestone in the field of pain management ... Journavx, from Vertex Pharmaceuticals, is first new class of acute ...

We recently published a list of Renaissance Technologies Portfolio: Top 10 Stock Picks. In this article, we are going to take ...

Vertex Pharmaceuticals Inc (VRTX) reports robust financial performance with significant revenue growth and strategic product ...